Making considered changes that will deliver benefits in the longer-term, regardless of any short- term disruption or pain, calls for...
SpliceBio CEO: The Route From US Academic To Spanish Gene Tech Entrepreneur
Startup Co-founder And CEO Explains The Difficult Process Of ‘Rolling Down The Sleeves’ And Allowing Strategic Activity To Take Precedence
Listen to this article
From an early stage in his career, Miquel Vila-Perelló saw himself as a research academic. It was an ambition he duly fulfilled. Later, seeing the greater potential to bring benefit to human health by forming his own company, he co-founded SpliceBio, a Spain-based startup focusing on gene therapies for rare diseases.
Candid conversations with C-suite leaders.
More from Business Strategy
• By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
• By
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.
• By
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
More from In Vivo
• By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
• By
The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
